GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » EV-to-FCF

Regenetp (Regenetp) EV-to-FCF : 0.11 (As of Jun. 08, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Regenetp EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Regenetp's Enterprise Value is $-2.39 Mil. Regenetp's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 was $-21.64 Mil. Therefore, Regenetp's EV-to-FCF for today is 0.11.

The historical rank and industry rank for Regenetp's EV-to-FCF or its related term are showing as below:

RGTPQ's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.405
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Regenetp's stock price is $0.142. Regenetp's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.670. Therefore, Regenetp's PE Ratio for today is At Loss.


Regenetp EV-to-FCF Historical Data

The historical data trend for Regenetp's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp EV-to-FCF Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.80 -0.82 -0.48 -1.36 0.15

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 0.46 0.35 0.15 -0.01

Competitive Comparison of Regenetp's EV-to-FCF

For the Biotechnology subindustry, Regenetp's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Regenetp's EV-to-FCF falls into.



Regenetp EV-to-FCF Calculation

Regenetp's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-2.394/-21.642
=0.11

Regenetp's current Enterprise Value is $-2.39 Mil.
Regenetp's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenetp  (OTCPK:RGTPQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Regenetp's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.142/-1.670
=At Loss

Regenetp's share price for today is $0.142.
Regenetp's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.670.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Regenetp EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Regenetp's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (Regenetp) Business Description

Traded in Other Exchanges
N/A
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
Executives
Peter A Cohen director 40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg director 1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague officer: Chief Operating Officer 1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler other: General Counsel 1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer director 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen director POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann officer: Chief Financial Officer C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson officer: Chief Financial Officer 14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough 10 percent owner, other: Prior D&O within 90 days 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann director 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson director, officer: Chief Operating Officer 181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan director 1943, ROSECREST DRIVE, OAKLAND CA 94602